Proceeds PurposesThe company intends to invest the proceeds from the Series A financing to advance its pipeline of novel rare-disease drug candidates, including a proof-of-concept study of RE-021 (a dual acting receptor antagonist of Angiotensin and Endothelin receptors) in Focal Segmental Glomerulosclerosis (FSGS) scheduled to begin enrolling patients during the second quarter of this year.